Displaying results 1 - 4 of 4
Clear search
Abzena launches EpiScreen® 2.0 Immunogenicity platform
Abzena launches EpiScreen® 2.0, a next generation immunogenicity tool for de-risking the development of complex biologics and bioconjugates.
Abzena announces major investment in Bioconjugation and ADC capabilities
Abzena announces major investment in Bioconjugation and ADC capabilities in response to increasing industry demand.
Abzena launches AbZelect CLD platforms
Abzena launches AbZelect™ platforms for improving cell line development efficiency on the pathway to IND.
Abzena appoints Thomas Castellano as Chief Financial Officer
Abzena, the leading end-to-end integrated CDMO for complex biologic molecules and Antibody Drug Conjugates (ADCs) has announced the appointment of Thomas Castellano, as Chief Financial Officer.